Loxoribine induces chronic lymphocytic leukemia B cells to traverse the cell cycle
Open Access
- 15 November 1994
- journal article
- Published by American Society of Hematology in Blood
- Vol. 84 (10) , 3457-3464
- https://doi.org/10.1182/blood.v84.10.3457.3457
Abstract
Leukemic B cells from a majority of patients with chronic lymphocytic leukemia (CLL) enter the cell cycle upon stimulation in vitro with loxoribine, a potent 7,8-disubstituted guanine ribonucleoside immunostimulant. In the absence of added costimulants, a proportion of these cells become activated and undergo DNA synthesis and mitosis accompanied by a marked increase in expression of an array of cell surface activation antigens. The resultant activated B-CLL cells exhibit greatly enhanced sensitivity to cycle-active cytotoxic drugs. This approach may be of potential value in the therapy of CLL.Keywords
This publication has 0 references indexed in Scilit: